论文部分内容阅读
采用人胎儿脾ＬＡＫ细胞治疗６２例晚期恶性肿瘤病人。结果表明人胎儿脾ＬＡＫ细胞的临床应用安全可行，多数病人在治疗期间一般状况得到改善。总缓解率为（ＰＲ）２２．５８％，平均缓解时间为１５．９５个月。缓解率与克氏评分和接受４次疗程的ＩＬ－２／ＬＡＫ细胞用量有关。在１８．４个月的治疗期间，死亡率为２０．９７％，平均生存期为１６．５０个月。ＩＬ－２／ＬＡＫ细胞对肾癌、黑色素瘤、结肠癌、肺癌和肝癌的转移灶有较好疗效，对原发灶也有一定作用。
62 cases of advanced malignant tumors were treated with human fetal spleen LAK cells. The results showed that the clinical application of human fetal spleen LAK cells safe and feasible, the majority of patients during the general condition has been improved. The overall response rate (PR) 22.58%, the average response time was 15.95 months. Mitigating rates were related to the Klinefelter score and the amount of IL-2 / LAK cells treated with 4 cycles. During 18.4 months of treatment, the mortality rate was 20.97% with an average survival of 16.50 months. IL-2 / LAK cells have a good effect on the metastasis of renal cell carcinoma, melanoma, colon cancer, lung cancer and liver cancer, and also play a role in the primary tumor.